Proteor to Expand Lower Limb Prosthetics Portfolio Through Its Acquisition of Freedom Innovations Assets
9.10.2020 21:58:00 EEST | Business Wire | Press release
Proteor USA, LLC, a wholly owned subsidiary of the France based, Proteor Group, has signed an agreement with Ottobock to acquire a significant portion of the lower limb prosthetics portfolio of Freedom Innovations which demonstrates Proteor’s continued commitment and investment in the worldwide prosthetic industry. The agreement was reached by Proteor and Ottobock at the end of September 2020 and the proposed transaction is anticipated to close by the end of 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201009005566/en/
Under the agreement, Proteor will expand substantially its lower limb prosthetics portfolio and acquire a range of Freedom Innovations’ flagship products, including the Plié3 microprocessor knee, the Kinnex and Kinterra ankles, and the Agilix, Highlander, Dynadapt, Sierra and Pacifica feet products.
Both Proteor and Freedom Innovations share a similar mission to increase the independence and well-being of people who use their products by offering innovative, high-performance solutions that deliver security, stability, and comfort for a reasonable price. Through the acquisition of a significant portion of Freedom Innovations, Proteor is eager to combine the teams in the United States and Europe and expand globally, thereby providing a clear choice to prosthetists and their patients for enhanced outcomes.
“We strongly believe in the long-term benefits of this move for the people we serve around the world. By combining the expertise of our teams in the US and Europe, the momentum we generate will continue to build Proteor’s presence within the O&P community,” said Edouard Archambeaud, COO and member of the Managing Board of Proteor.
Matthew Swiggum, President and CEO of Proteor USA states, “We are dedicated to providing inventive, dependable products to the orthotic and prosthetic community that offer increased independence with an outstanding product portfolio. Working with the passionate and skilled team at Freedom Innovations is a pleasure we’re all looking forward to.”
For Proteor, the proposed transaction will reinforce its positioning and growth strategy worldwide, while creating synergies within innovation platforms, significant continuous R&D investment, and a focus on mechatronic lower limb solutions. This proposed transaction will further build upon Proteor’s presence in the United States lower limb prosthetics market, already strengthened by Proteor’s prior acquisition of Ability Dynamics’ RUSH Foot portfolio, which further illustrates Proteor’s commitment to its markets worldwide.
The terms of the proposed transaction between Proteor and Ottobock remain subject to the final approval of the Commissioners of the U.S. Federal Trade Commission (FTC) and are meant to satisfy Ottobock’s obligations under the Order from the FTC to divest certain assets from the U.S. company Freedom Innovations. Once approval from the FTC is obtained, Proteor USA will integrate a significant number of Freedom Innovations team members in manufacturing, sales, marketing, R&D and clinical from Gunnison, Utah; Irvine, California; and Germany.
About Proteor
Proteor, an independent family-company, was established 105 years ago with its headquarters in Dijon, France. Proteor operates in the O&P market with three key areas of activities: software’s, components and custom-made devices. Thanks to continuous investments in innovation, many medical and scientific partnerships, and day to day cooperation with CPOs, Proteor enjoys a recognized expertise all over the O&P community.
For additional information visit http://proteorusa.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201009005566/en/
Contact information
Media:
Sophie Desbois
Sophie.desbois@proteor.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 14:00:00 EEST | Press release
Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performance, reliability and trusted supply chains. Its drones support national security and public-safety operations, sear
Enhertu ® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 14:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from theDESTINY-Breast09 phase 3 trialpresented at the 2025 American Society of Clinical Oncology Annual Meeting and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DESTI
SLB Announces Second-Quarter 2026 Results24.7.2026 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas. Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8,721 $8,546 3% 5% Income before taxes - GAAP basis $1,018 $956 $1,285 6% -21% Income before taxes margin - GAAP basis 11.3% 11.0% 15.0% 38 bps -369 bps Net income attributable to SLB - GAAP basis $786 $752 $1,014 5% -22% Diluted EPS - GAAP basis $0.52 $0.50 $0.74 4% -30% Adjusted EBITDA* $1,899 $1,773 $2,051 7% -7% Adjusted EBITDA margin* 21.2% 20.3% 24.0% 83 bps -284 bps Pretax segment operating income* $1,404 $1,321 $1,584 6% -11% Pretax segment operating margin* 15.6% 15.2% 18.5% 49 bps -289 bps Net income attributable to SLB, excluding charges & credits* $833 $783 $1,0
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 13:30:00 EEST | Press release
NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps businesses realize the full value of NIQ's trusted market intelligence by automatically surfacing the trends, opportunities and
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 11:05:00 EEST | Press release
In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-government agreement, funded under the European Union’s SAFE programme, underlines the high level of partnership between France and Romania. The first delivery is expected in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260724603527/en/ The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200MM/A) radars to protect the Romanian airspace. The GM200 MM/A is a combat-proven medium-range 4D AESA radar, already deployed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
